Blood cancers, Cell type, Low grade lymphoma, Lymphoma, Non-Hodgkin lymphoma (NHL)
Results
Phase 3
This trial looked at adding lenalidomide to rituximab for follicular or marginal zone lymphoma. It was for people whose lymphoma had got worse or come back despite treatment.
The trial was open for people to join between 2014 and 2015. The team published the results in 2019.
Recruitment start: 1 April 2014
Recruitment end: 22 July 2015
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor John Gribben
Celgene Corporation
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Last reviewed: 19 Sept 2023
CRUK internal database number: 11325
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
